| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 03-13-2024 | 12-31-2023 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $9 price target.
Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy.
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical tr...
Guggenheim analyst Michael Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Buy rating and announces Price ...
RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday.
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0....
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...
